• 1
    Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003; CD000543.
  • 2
    Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97: 1398407.
  • 3
    Stoa-Birketvedt G, Florholmen J. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Aliment Pharmacol Ther 1999; 13: 35761.
  • 4
    Stretch GL, Campbell BJ, Dwarakanath AD, et al. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther 1996; 10: 9417.
  • 5
    Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003; 17: 2942.
  • 6
    Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 17989.
  • 7
    Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001; 7: 23742.
  • 8
    Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993; 88: 118897.
  • 9
    Miner P, Nostrant T, Wruble L, et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterol 1991; 100: A231.
  • 10
    Kruis W, Brandes J-W, Schreiber S, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 70715.
  • 11
    Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1: 3643.
  • 12
    Maier K, Frühmorgen P, Bode JC, Heller T, von Gaisberg U, Klotz U. Erfolgreiche Akutbehandlung chronisch-entzündlicher Darmerkrankungen mit oraler 5-Aminosalicylsäure. Dtsch Med Wschr 1985; 110: 3638.
  • 13
    Maier K, von Gaisberg U, Klotz U. 5-Aminosalizylsäure-Tabletten (Salofalk, Claversal). Verdauungskrankh 1985; 3: 25960.
  • 14
    Rachmilewicz D. Coated mesalazine (5-aminosalcylic acid) versus sulphasalazine in the treatment of active ulcerative colitis. Br Med J 1989; 289: 826.
  • 15
    Christensen LA. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man. Dan Med Bull 2000; 47: 2041.
  • 16
    Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001; 49: 7839.
  • 17
    Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining of ulcerative colitis. Aliment Pharmacol Ther 1989; 3: 18391.
  • 18
    Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant to sulfasalazine A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987; 93: 125562.
  • 19
    Marsaglia G, Bray TA. One-Line Random Number Generators and their Use in Combinations. Mathematical Note no. 551. Seattle, WA: Mathematics Research Laboratory, Boeing Scientific Research Laboratories, 1968.
  • 20
    Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 1748.
  • 21
    Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990; 9: 144754.
  • 22
    Marakhovski Y, Fixa B, Holoman J, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 13340.
  • 23
    Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004; 10: 84859.
  • 24
    Minocha A, Mokshagundam S, Gallo SH, Rahal PS. Alterations in upper gastrointestinal motility in Helicobacter pylori-positive nonulcer dyspepsia. Am J Gastroenterol 1994; 90: 135860.
  • 25
    Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16 (Suppl. 1): 315.
  • 26
    Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57: 26779.